Day One: Pediatric Brain Cancer Candidate Shows Encouraging Responses
- Day One Biopharmaceuticals announced topline results from the ongoing Phase 2 FIREFLY-1 trial evaluating tovorafenib (DAY101) as a monotherapy in recurrent or progressive pediatric low-grade glioma (pLGG).
- Pediatric low-grade glioma is the most common brain tumor diagnosed in children.
- Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023.
- Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% were observed in 69 heavily-pretreated, RANO-evaluable patients.
- Based on 77 treated patients, safety data indicated monotherapy tovorafenib to be generally well-tolerated.
- The most common side effects reported related to tovorafenib were change in hair color (75%), increased creatine phosphokinase (64%), anemia (46%), fatigue (42%), and maculopapular rash (42%).
- In addition to FIREFLY-1, Day One is expanding the development of tovorafenib as a front-line therapy for patients newly diagnosed with pLGG.
- The global, Phase 3, registrational FIREFLY-2/LOGGIC clinical trial is evaluating once-weekly monotherapy tovorafenib in newly-diagnosed patients with pLGG harboring a known activating RAF alteration.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.